GLP-1 Bloodwork: What to Test on Semaglutide

GLP-1 receptor agonists have gone from niche diabetes drugs to the most talked-about compounds in bodybuilding. Semaglutide, tirzepatide, and now retatrutide are showing up in cutting protocols everywhere, and for good reason: they crush appetite, strip fat, and improve nearly every metabolic marker on your bloodwork panel.

Most GLP-1 monitoring guides are written for diabetic patients under close physician supervision. If you're an athlete using these compounds for body composition, especially alongside TRT or other PEDs, the standard advice doesn't cover what you actually need to watch. Up to 40% of weight lost on semaglutide can be lean mass (Wilding et al., 2021), your estradiol levels will shift as fat disappears, and pancreatic enzyme elevations will show up on bloodwork that look alarming but are usually harmless.

This guide covers which markers to test, when to test them, and what the results actually mean for someone using GLP-1 agonists in a performance context.

What Blood Tests Do You Need Before Starting GLP-1?

Before your first injection, you need a baseline panel. This is your reference point for tracking every change the drug causes, both positive and negative.

The essential baseline panel:

• Metabolic: Fasting glucose, HbA1c, fasting insulin
• Liver: ALT, AST, GGT
• Kidney: Creatinine, eGFR
• Lipids: HDL, LDL, Triglycerides
• Pancreatic: Amylase, lipase
• Thyroid: TSH, free T4
• Inflammation: CRP

If you're on TRT, add: Total testosterone, free testosterone, estradiol, SHBG, haematocrit.

Before prescribing, you need to rule out absolute contraindications: personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). This is a black box warning on all GLP-1 agonists. If you have a history of pancreatitis, discuss risk factors with your provider before starting.

Essential Markers to Track on GLP-1 Therapy

Metabolic Panel: Fasting Glucose, HbA1c, Insulin

GLP-1 agonists shine here. Semaglutide reduces HbA1c by 1.5-1.8% over 30-56 weeks. Tirzepatide is even more potent, with reductions of 2.0-2.3% in the SURPASS-2 trial, outperforming semaglutide head-to-head (Frías et al., 2021).

Even if you're not diabetic, these markers matter. Fasting glucose and insulin are proxies for insulin sensitivity, which affects everything from nutrient partitioning to recovery. GLP-1 therapy drives fasting glucose down and improves HOMA-IR scores, making your metabolism more efficient at shuttling nutrients into muscle rather than fat.

If you're also running GH, fasting glucose may not drop as expected because growth hormone is diabetogenic. The GLP-1 can mask GH-induced insulin resistance, so check fasting insulin alongside glucose to get the real picture.

Liver Function: ALT, AST, GGT

GLP-1 agonists typically improve liver enzymes, not worsen them. A meta-analysis of 11 RCTs found significant reductions in ALT, AST, and GGT, with liver fat content dropping by nearly 4% (Mantovani et al., 2021).

If you're using oral AAS that stress the liver, GLP-1 therapy may partially offset hepatotoxicity through fat loss and improved insulin signaling. Don't use GLP-1 as liver protection, though. Get baseline liver enzymes so you can track the trajectory. Declining ALT and GGT on GLP-1 is a sign that therapy is working metabolically.

Kidney Function: Creatinine, eGFR

GLP-1 agonists have renoprotective effects long-term. Tirzepatide nearly halved the risk of composite kidney endpoints in the SURPASS-4 post-hoc analysis (Bosch et al., 2023).

There's a short-term risk: GI side effects. Nausea hits 15-44% of users, vomiting 5-24%, and diarrhoea 8-30%, especially during dose titration. Persistent vomiting or diarrhoea causes dehydration, and dehydration can cause acute kidney injury. The FDA now requires kidney injury warnings on all GLP-1 labels.

If you're in a caloric deficit, training hard, and dealing with GLP-1-induced nausea, you're tripling your dehydration risk. Monitor creatinine and eGFR at 4-6 weeks after starting or increasing dose. If creatinine spikes with GI symptoms, hydrate aggressively and consider holding the dose.

Lipid Panel: HDL, LDL, Triglycerides

GLP-1 agonists improve your lipid profile across the board. A network meta-analysis of 26 trials found total cholesterol dropped 5.2%, LDL fell 4-8%, and triglycerides dropped 13-20% (Chae et al., 2024). Dual agonists like tirzepatide showed even greater improvements.

This is particularly relevant if you're running compounds that hammer lipids (oral AAS, high-dose testosterone, trenbolone). The GLP-1 won't fully counteract those effects, but it provides a meaningful buffer. Track triglycerides especially, as severe hypertriglyceridemia (>500 mg/dL) is a pancreatitis risk factor.

Pancreatic Enzymes: Amylase and Lipase

Lipase commonly increases 28-31% and amylase rises about 7% (Steinberg et al., 2017). Elevated pancreatic enzyme readings are common during treatment. This scares people more than any other marker on GLP-1 bloodwork.

These elevations are a pharmacological effect of the drug, not a sign of disease. The positive predictive value for actual pancreatitis is less than 1%. We cover this in detail in the pancreatitis section below.

Get baseline levels. Without knowing where you started, you can't tell if a lipase of 80 U/L is a normal bump or a concerning jump.

Thyroid Function: TSH, fT4

All GLP-1 agonists carry a black box warning for medullary thyroid carcinoma based on rodent studies. In humans, the picture is more nuanced. A French cohort study found a modest association between 1-3 years of GLP-1 use and thyroid cancer risk (adjusted HR 1.58) (Bezin et al., 2023), but 3-year cardiovascular outcome trials showed no changes in calcitonin levels.

Routine calcitonin screening is not recommended for most users. The false-positive rate is too high and the positive predictive value too low. Instead, get baseline TSH and free T4 to monitor thyroid function, and only pursue calcitonin if you have risk factors (family history of MTC/MEN 2, thyroid nodules).

Inflammation: CRP

GLP-1 agonists are genuinely anti-inflammatory. The STEP trials showed semaglutide reduced CRP by 39-48% compared to placebo (Verma et al., 2022). CRP reductions correlated with weight and glucose improvements, but the magnitude of the drop suggests additional direct anti-inflammatory effects beyond metabolic changes alone.

For athletes using anabolic compounds that raise systemic inflammation, tracking CRP on GLP-1 gives you a useful measure of overall inflammatory burden. A dropping CRP is a strong signal that your metabolic health is trending in the right direction.

Can GLP-1 Medications Cause Pancreatitis?

This question comes up constantly, so here are the real numbers.

Meta-analyses of randomised controlled trials show no increased pancreatitis risk with semaglutide (OR 0.7, 95% CI 0.5-1.2) or tirzepatide compared to placebo (Steinberg et al., 2017). The LEADER trial tracked over 9,300 patients on liraglutide for nearly 4 years and found 0.4% incidence in the treatment group versus 0.5% on placebo. Numerically fewer cases on the drug.

A lipase increase of 28-31% is expected. Up to 8.3% of patients will have lipase readings above 3x the upper limit of normal without any clinical signs of pancreatitis. These elevations stabilise by 6 months and reverse after stopping the drug.

Acute pancreatitis requires 2 of 3 criteria: (1) severe abdominal pain, typically radiating to the back, (2) amylase or lipase greater than 3x the upper limit of normal, and (3) characteristic CT findings. If you have severe abdominal pain on a GLP-1 agonist, stop the medication and get to an emergency department. Don't wait for bloodwork.

The real risk factor is gallstones. GLP-1 agonists increase gallbladder disease risk by 37%, and that jumps to 129% during rapid weight loss (He et al., 2022). Gallstones cause roughly 30% of all pancreatitis cases. If you're losing more than 1 kg per week, the gallstone risk, not the drug itself, is your primary concern.

Semaglutide vs. Tirzepatide vs. Retatrutide: Monitoring Differences

The differences between these compounds matter for your bloodwork.

Semaglutide: The Standard

Semaglutide is a pure GLP-1 receptor agonist. It's the most studied, most widely available, and produces solid results: 14.9% body weight reduction in the STEP 1 trial (Wilding et al., 2021). Standard monitoring covers your metabolic panel, liver enzymes, kidney function, lipids, and pancreatic enzymes.

The main drawback for athletes is body composition: approximately 40% of weight lost on semaglutide is lean mass, the worst ratio of the three compounds. GI side effect discontinuation rates are also higher than tirzepatide (5.6% vs 2.7% in SURMOUNT-5).

Tirzepatide: Best for Body Composition

Tirzepatide is a dual GIP/GLP-1 receptor agonist that outperforms semaglutide on nearly every metric. In the SURMOUNT-5 head-to-head trial, tirzepatide achieved 20.2% weight loss versus 13.7% for semaglutide (Aronne et al., 2025).

The body composition data is what makes tirzepatide the preferred choice for physique athletes. In SURMOUNT-1, approximately 75% of weight lost was fat mass and only 25% was lean mass (Look et al., 2025), a significantly better ratio than semaglutide's 60/40 split. Emerging data also suggests tirzepatide reduces muscle fat infiltration, improving muscle quality even as total lean mass decreases.

Same monitoring panel as semaglutide, with greater expected improvements in lipids and glycaemic markers.

Retatrutide: Most Potent, Most Monitoring

Retatrutide is the triple agonist: GLP-1, GIP, and glucagon receptors. Phase 2 data showed 24.2% weight loss at 48 weeks, exceeding both semaglutide and tirzepatide (Jastreboff et al., 2023).

The glucagon receptor component sets retatrutide apart, and it also demands extra monitoring:

• Heart rate: Retatrutide causes dose-dependent heart rate increases, peaking at week 24. If you're also using clenbuterol, high-dose T3, or stimulants, this is a serious stacking concern. Track resting heart rate weekly with a wearable.
• Liver enzymes: The glucagon component drives hepatic fatty acid oxidation. Retatrutide reduced liver fat by 82% at the highest dose (Sanyal et al., 2024). This is a massive benefit for anyone with fatty liver from oral steroid use, but check ALT/AST more frequently during the first 24 weeks when hepatic effects peak.
• Beta-hydroxybutyrate: This ketone body marker increases 2-3 fold on retatrutide, reflecting increased fat oxidation. Optional, but useful for confirming the glucagon pathway is active.

Bottom line for compound selection:

Muscle Preservation: The Missing Piece

The STEP 1 DXA substudy showed 40% of weight lost on semaglutide was lean mass. This is not inevitable. A 2025 case series documented three patients who combined high protein intake (up to 1.7 g/kg/day) with resistance training (3-5 days/week) and achieved dramatically better results: two patients actually gained lean mass despite losing 13-27% of total body weight (Tinsley & Nadolsky, 2025).

Protein: The Non-Negotiable

Research on athletes during caloric restriction shows 2.3 g/kg protein is significantly superior to 1.0 g/kg for maintaining lean body mass (Mettler et al., 2010). For bodybuilders on GLP-1, aim for the higher end: 1.8-2.3 g/kg per day.

The challenge is that GLP-1 agonists crush your appetite and slow gastric emptying, making it physically difficult to eat enough protein. Prioritise protein at every meal, use liquid protein sources (shakes, broths) that are easier to tolerate, and spread intake across 4-5 smaller meals.

Resistance Training: More Important Than the Drug

Resistance training, not cardio, is what preserves lean mass during weight loss. The case series patients all trained 3-5 days per week with structured resistance protocols. Combined with high protein, this is the single most effective intervention against GLP-1-induced muscle loss.

Bloodwork Markers for Tracking Muscle Loss

Declining creatinine on GLP-1 may signal muscle loss, not improved kidney function. Creatinine is produced by muscle tissue, so as muscle mass drops, serum creatinine falls and eGFR artificially inflates. If your creatinine is trending down alongside weight loss, consider cystatin C testing for a muscle-independent measure of kidney function.

Track these alongside DEXA scans:

• Creatinine trend (declining = potential muscle loss)
• Albumin (nutritional status marker)
• Free testosterone (if on TRT, ensure levels support anabolism)

GLP-1 + TRT Stack: What Changes?

Combining GLP-1 agonists with TRT is one of the most common real-world protocols in the bodybuilding community. The fat loss from GLP-1 triggers several hormonal shifts that directly affect TRT management.

Aromatase Activity Drops With Fat Loss

Fat tissue produces aromatase, the enzyme that converts testosterone to estradiol. Less fat means less aromatase, which means less estradiol production (Cohen, 2001). If you're taking an aromatase inhibitor (anastrozole, exemestane) to manage E2 on TRT, you may need to reduce your AI dose by 25-50% during active GLP-1 weight loss to prevent crashing estradiol below the optimal range.

Watch symptoms over numbers during transition. As your body fat changes, your optimal estradiol level shifts too. Libido, joint health, mood, and erectile function are better guides than chasing a specific E2 number during active fat loss.

SHBG Rises, Free Testosterone Falls

Weight loss significantly increases SHBG (Mucinski et al., 2025). One study found SHBG nearly doubled during aggressive dieting, from 27.6 to 48.1 nmol/L (Niskanen et al., 2004).

Higher SHBG binds more testosterone, reducing free testosterone and bioavailable T despite stable total testosterone levels. Check free testosterone (calculated via Vermeulen equation or measured directly) every 8-12 weeks during active weight loss. You may need a 10-20% TRT dose increase to maintain free T in the optimal range.

The GH + GLP-1 Glucose Tug-of-War

Growth hormone is diabetogenic. It raises fasting glucose and induces insulin resistance through the glucose-fatty acid cycle (Bramnert et al., 2003). GLP-1 does the opposite. When you run both, the effects partially cancel out, creating unpredictable glucose patterns.

If you're using GH alongside GLP-1, test fasting glucose and fasting insulin every 4 weeks. Don't assume the GLP-1 has your glucose handled just because HbA1c looks normal. HbA1c is a 3-month average; it can mask fasting spikes from GH. For athletes also using exogenous insulin, reduce doses by 20-30% when adding GLP-1 to avoid hypoglycaemia.

Combined TRT + GLP-1 Monitoring Panel

How Often Should You Get Blood Work on GLP-1?

Practical testing timeline:

Baseline (before first dose): Full panel as described above. This is your reference for everything that follows.

4-6 weeks (early titration): Kidney function (creatinine, eGFR) and electrolytes. This catches dehydration-related issues from GI side effects during dose escalation. If you're on TRT, add estradiol and free testosterone.

12-16 weeks (assessing efficacy): Repeat the full panel. By now you'll see the metabolic improvements: HbA1c trending down, lipids improving, liver enzymes dropping. Compare pancreatic enzymes to baseline to establish your new normal on the drug. Get a DEXA scan to assess body composition changes.

6-month maintenance: Full panel plus DEXA. Pancreatic enzymes should have stabilised. If everything looks good, move to every 6 months for ongoing monitoring.

Any time symptoms arise: Severe abdominal pain, persistent vomiting or diarrhoea (>48 hours), signs of dehydration, or unexplained fatigue warrant immediate testing, not waiting for the next scheduled panel.

Practical Recommendations

Tier 1: Essential for all GLP-1 users

• Metabolic panel (glucose, HbA1c), liver enzymes (ALT, AST, GGT), kidney function (creatinine, eGFR), lipid panel, CRP
• Test at baseline, 12 weeks, then every 6 months

Tier 2: Recommended for athletes and PED users

• Pancreatic enzymes (amylase, lipase), thyroid panel (TSH, fT4), DEXA scan, free testosterone + SHBG (if on TRT), estradiol (if on TRT)
• Test at baseline and 12 weeks minimum

Tier 3: Situational

• Cystatin C (if creatinine is declining and you suspect muscle loss)
• Calcitonin (only if family history of MTC/MEN 2)
• Fasting insulin (if also using GH)
• Heart rate monitoring (if using retatrutide)
• Electrolytes (if persistent GI symptoms)

If you're already doing regular bloodwork for TRT or a cycle, adding GLP-1 monitoring is straightforward. Most of the markers overlap. The main additions are pancreatic enzymes, which aren't part of a standard hormone panel, and more frequent estradiol checks during active weight loss.

Key Takeaways

• Baseline testing is non-negotiable. You need a reference point for every marker before your first GLP-1 injection. Without it, you're guessing at what's changed.
• Pancreatic enzyme elevations are normal. Lipase increases 28-31% on GLP-1 therapy. The positive predictive value for actual pancreatitis is less than 1%. Don't panic at mildly elevated numbers.
• Tirzepatide preserves more muscle than semaglutide. 75% fat loss versus 60% in body composition studies. For physique athletes, this matters.
• Retatrutide is the most potent but needs extra monitoring. The glucagon component adds heart rate and liver enzyme monitoring requirements that semaglutide and tirzepatide don't.
• Declining creatinine may mean muscle loss, not better kidneys. Use cystatin C for accurate kidney assessment during weight loss.
• On TRT, re-evaluate your AI dose and free testosterone every 6-8 weeks. Fat loss reduces aromatase activity and raises SHBG, changing your entire hormonal balance.
• Protein intake of 1.8-2.3 g/kg/day and resistance training 3-5x/week are the best defences against lean mass loss. The drug doesn't determine body composition outcomes; your training and nutrition do.
• GH + GLP-1 requires glucose vigilance. Opposing effects on insulin sensitivity create unpredictable patterns. Check fasting glucose and insulin monthly.

For a deeper dive into general bloodwork interpretation for athletes, see our Complete Guide to Bloodwork for Bodybuilders. If you're also managing estradiol on TRT, our Estradiol on TRT guide covers AI dosing and E2 management in detail. And for haematocrit concerns on TRT, check out TRT, Haemoglobin, and Haematocrit.

---

References

1. Aronne, L. J., Bade Horn, D., le Roux, C. W., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 393(1), 26-36. PubMed

2. Bezin, J., Gouverneur, A., Pénichon, M., et al. (2023). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care, 46(2), 384-390. PubMed

3. Bosch, C., Carriazo, S., Soler, M. J., Ortiz, A., & Fernandez-Fernandez, B. (2023). Tirzepatide and prevention of chronic kidney disease. Clinical Kidney Journal, 16(5), 797-808. PubMed

4. Bramnert, M., Segerlantz, M., Laurila, E., et al. (2003). Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. Journal of Clinical Endocrinology & Metabolism, 88(4), 1455-1463. PubMed

5. Chae, Y., Kwon, S. H., Nam, J. H., et al. (2024). Lipid profile changes induced by GLP-1 receptor agonists in patients with type 2 diabetes. Expert Review of Clinical Pharmacology, 17(8), 721-729. PubMed

6. Cohen, P. G. (2001). Aromatase, adiposity, aging and disease. Medical Hypotheses, 56(6), 702-708. PubMed

7. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. PubMed

8. He, L., Wang, J., Ping, F., et al. (2022). Association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases. JAMA Internal Medicine, 182(5), 513-519. PubMed

9. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PubMed

10. Look, M., Dunn, J. P., Kushner, R. F., et al. (2025). Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes, Obesity and Metabolism, 27(5), 2720-2729. PubMed

11. Mantovani, A., Petracca, G., Beatrice, G., et al. (2021). GLP-1 receptor agonists for treatment of NAFLD and NASH: An updated meta-analysis. Metabolites, 11(2), 73. PubMed

12. Mettler, S., Mitchell, N., & Tipton, K. D. (2010). Increased protein intake reduces lean body mass loss during weight loss in athletes. Medicine & Science in Sports & Exercise, 42(2), 326-337. PubMed

13. Mucinski, J. M., Kelley, D. E., Winters, S. J., & Goodpaster, B. H. (2025). Effects of weight loss on testosterone, SHBG, adiposity, and insulin sensitivity. Obesity, 33(5), 962-973. PubMed

14. Niskanen, L., Laaksonen, D. E., Punnonen, K., et al. (2004). Changes in SHBG and testosterone during weight loss in abdominally obese men. Diabetes, Obesity and Metabolism, 6(3), 208-215. PubMed

15. Sanyal, A. J., Kaplan, L. M., Frias, J. P., et al. (2024). Retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nature Medicine, 30(7), 2037-2048. PubMed

16. Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., et al. (2017). Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: Results from the LEADER randomized trial. Diabetes Care, 40(7), 966-972. PubMed

17. Tinsley, G. M., & Nadolsky, S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports, 13. PubMed

18. Verma, S., Bhatta, M., Davies, M., et al. (2022). Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity. EClinicalMedicine, 55, 101737. PubMed

19. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. PubMed